Axis of Evil

Showing 4404 articles
Business

C4 Therapeutics: Can Its Protein-Degrading Tech Ignite a Biotech Rally?

Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.

Business

Argan, Inc. (AGX): The Quiet Powerhouse in Energy Infrastructure

Argan, Inc., a specialized engineering and construction firm, is drawing investor attention with its robust financial performance, zero-debt balance sheet, and strategic positioning in the evolving energy sector. Despite a premium valuation, its record backlog and cash-generating prowess present a compelling bull case.

Business

Ziff Davis: A Deep-Value Play or a Digital Media Trap?

Ziff Davis (ZD) shares are attracting value investors with a seemingly cheap valuation and potential asset sales. However, underlying concerns about revenue quality, customer churn, and existential threats from AI-driven search shifts paint a more complex picture for the digital media conglomerate.

Business

AerCap Holdings: The Aviation Giant Flying Under the Radar

AerCap Holdings N.V., the world's largest aircraft lessor, is drawing renewed attention from value investors. Despite geopolitical headwinds and a cyclical reputation, its robust cash flows, industry dominance, and compelling valuation present a strong case for a rerating, as global travel demand outpaces constrained aircraft supply.